|
Title
|
|
|
|
The role of gemcitabine in the treatment of malignant mesothelioma
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Gemcitabine is broadly active in a variety of solid tumors, including malignant mesothelioma. In vitro, gemcitabine demonstrates activity against mesothelioma cell lines. The role of single-agent gemcitabine in patients with mesothelioma is unclear, since three phase II trials treated a total of 60 patients and achieved response rates of 0%, 7%, and 31%. The combination of gemcitabine and cisplatin is synergistic against mesothelioma cell lines in vitro. Gemcitabine in combination with cisplatin or carboplatin shows definite activity in phase II trials. The trial by Byrne and colleagues that demonstrated a response rate of 48% established the combination of gemcitabine plus cisplatin as a standard therapy for this disease in the United States. Subsequent multicenter trials have achieved lower response rates of 26% and 16% for this combination. Gemcitabine plus carboplatin also has activity. Future roles for gemcitabine in malignant mesothelioma patients include incorporating a gemcitabine/platinum regimen for neoadjuvant or adjuvant therapy, combining it with other cytotoxic chemotherapy agents such as pemetrexed or vinorelbine, or adding novel cytostatic agents such as the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, to the gemcitabine and platinating agent combination. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Seminars in oncology. - New York, N.Y., 1974, currens
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2002
| |
|
ISSN
|
|
|
|
0093-7754
[print]
1532-8708
[online]
| |
|
DOI
|
|
|
|
10.1053/SONC.2002.30232
| |
|
Volume/pages
|
|
|
|
29
:1
(2002)
, p. 70-76
| |
|
ISI
|
|
|
|
000173885200009
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|